Berkeley Capital Partners LLC Raises Position in Novartis AG (NYSE:NVS)
Berkeley Capital Partners LLC Raises Position in Novartis AG (NYSE:NVS)
Berkeley Capital Partners LLC boosted its stake in Novartis AG (NYSE:NVS – Get Rating) by 226.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,557 shares of the company's stock after buying an additional 8,713 shares during the quarter. Berkeley Capital Partners LLC's holdings in Novartis were worth $1,102,000 at the end of the most recent reporting period.
伯克利资本合伙公司最近向美国证券交易委员会提交的13F文件显示，今年第一季度，该公司将其在诺华制药(纽约证券交易所代码：NVS-GET Rating)的持股比例提高了226.7%。该机构投资者在本季度额外购买了8,713股后，持有该公司12,557股股票。在最近一个报告期结束时，Berkeley Capital Partners LLC持有的诺华公司股份价值1,102,000美元。
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. AHL Investment Management Inc. purchased a new position in Novartis in the 4th quarter worth approximately $25,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in Novartis in the 4th quarter worth approximately $32,000. Atwood & Palmer Inc. lifted its stake in Novartis by 400.0% in the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock worth $33,000 after purchasing an additional 300 shares in the last quarter. DeDora Capital Inc. purchased a new position in Novartis in the 1st quarter worth approximately $34,000. Finally, Allegheny Financial Group LTD acquired a new stake in shares of Novartis during the 4th quarter worth approximately $34,000. 9.40% of the stock is owned by hedge funds and other institutional investors.
一些其他对冲基金和其他机构投资者最近也买卖了该股的股票。AHL投资管理公司在第四季度购买了诺华公司价值约25,000美元的新头寸。Dixon Hughes Goodman Wealth Advisors LLC在第四季度购买了诺华公司的一个新头寸，价值约3.2万美元。今年第一季度，阿特伍德-帕尔默公司增持诺华股份400.0%。Atwood&Palmer Inc.现在持有375股该公司股票，价值3.3万美元，该公司在上个季度又购买了300股。DeDora Capital Inc.在第一季度购买了诺华公司的一个新头寸，价值约3.4万美元。最后，阿勒格尼金融集团有限公司在第四季度收购了价值约3.4万美元的诺华公司新股。该公司9.40%的股票由对冲基金和其他机构投资者持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of analysts have recently issued reports on NVS shares. Wolfe Research downgraded shares of Novartis from an "outperform" rating to a "market perform" rating in a report on Monday, May 9th. Credit Suisse Group raised their price target on shares of Novartis from CHF 85 to CHF 88 in a report on Thursday, April 28th. JPMorgan Chase & Co. raised their price target on shares of Novartis from CHF 80 to CHF 81 and gave the stock an "underweight" rating in a report on Wednesday, July 20th. upgraded shares of Novartis from a "hold" rating to a "buy" rating in a report on Thursday, April 14th. Finally, UBS Group lifted their target price on shares of Novartis from CHF 85 to CHF 88 and gave the company a "neutral" rating in a report on Wednesday, April 27th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $87.33.
一些分析师最近发布了关于NVS股票的报告。沃尔夫研究公司在5月9日星期一的一份报告中将诺华公司的股票评级从“跑赢大盘”下调至“市场表现”。瑞士信贷集团在4月28日星期四的一份报告中将诺华公司的股票目标价从85瑞士法郎上调至88瑞士法郎。摩根大通在7月20日星期三的一份报告中将诺华公司的股票目标价从80瑞士法郎上调至81瑞士法郎，并将该股的评级定为“减持”。在4月14日周四的一份报告中，诺华公司的股票评级从持有上调至买入。最后，瑞银集团在4月27日星期三的一份报告中将诺华公司的股票目标价从85瑞士法郎上调至88瑞士法郎，并给予该公司“中性”评级。两名研究分析师对该股的评级为卖出，8名分析师给予持有评级，3名分析师给予买入评级，一名分析师给予该公司强烈买入评级。根据MarketBeat.com的数据，该股的共识评级为持有，共识目标价为87.33美元。
Novartis Stock Performance
诺华公司股票表现
Novartis (NYSE:NVS – Get Rating) last released its quarterly earnings data on Monday, July 18th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.04. The business had revenue of $12.78 billion during the quarter, compared to analysts' expectations of $12.78 billion. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.64 EPS. As a group, equities analysts anticipate that Novartis AG will post 6.06 earnings per share for the current fiscal year.
诺华公司(纽约证券交易所代码：NVS-GET Rating)最近一次发布季度收益数据是在7月18日星期一。该公司公布本季度每股收益(EPS)为1.56美元，比普遍预期的1.52美元高出0.04美元。该业务当季营收为127.8亿美元，高于分析师预期的127.8亿美元。诺华的净利润率为44.31%，股本回报率为21.88%。该公司本季度营收同比下降1.4%。去年同期，该公司每股收益为1.64美元。作为一个整体，股票分析师预计诺华制药本财年的每股收益将达到6.06欧元。
Novartis Company Profile
诺华公司简介
(Get Rating)
(获取评级)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
诺华制药在全球研究、开发、制造和营销保健品。该公司通过两个部门运营，创新药品和Sandoz。创新药品部门为患者和医疗保健提供者提供处方药。它还提供眼科、神经科学、免疫学、肝科、皮肤科、呼吸科、心血管、肾脏和新陈代谢药物产品。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter's Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
- 免费获取StockNews.com关于诺华(Novartis)的研究报告
- MarketBeat：回顾一周7/25-7/29
- 宝洁第四季度收益开始疲软
- 在投资INTC股票之前，你必须问一个问题
- 家得宝：引领熊市的美丽而乏味的股票
- CRISPR治疗公司可能是隐藏在平坦视线中的登月计划吗？
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受诺华日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对诺华和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。